Asthma Real World Evidence
Applying Latest Guidelines and Recommendations to Initiate Biologic Therapy and Control Moderate to Severe Asthma Symptoms
Speakers: Reynold Panettieri, Jr, MD, Professor of Medicine, Vice Chancellor, Translational Medicine and Science (TMS)Nicola Hanania, MD, MS, Professor, Pulmonary and Critical Care Medicine
Duration: 60 minutes
Presented on: November 29, 2022
Reynold Panettieri, Jr, MD
Reynold Panettieri, Jr, MD
Professor of Medicine, Vice Chancellor, Translational Medicine and Science (TMS)Reynold Panettieri, Jr, MD, is the Professor of Medicine, Vice Chancellor for Translational Medicine and Science (TMS), and Director of the Rutgers Institute for TMS. He is the Principal Investigator of New Jersey Alliance for Clinical and Translational Science, New Jersey’s only CTSA Hub. His clinical practice is dedicated to patients with severe airways diseases. Dr. Panettieri is a skilled cell and molecular biologist focused on the role of airway smooth muscle function in severe airways diseases such as COPD. His laboratory pioneered human cell and tissue models to identify new therapeutic targets to promote bronchodilation and to ameliorate airway inflammation. Dr. Panettieri’s lab studies the way toxicants mediate airway hyperresponsiveness and steroid insensitivity in lung disease.
Nicola Hanania, MD, MS
Nicola Hanania, MD, MS
Professor, Pulmonary and Critical Care MedicineNicola Hanania, MD, MS, is Professor of Medicine of Pulmonary and Critical Care Medicine and Director of the Airways Clinical Research Center (ACRC) at Baylor College of Medicine in Houston, Texas. He serves on the Faculty Senate at Baylor and is the Chief of Section of Pulmonary, Critical Care and Sleep Medicine at Ben Taub Hospital. Dr. Hanania’s research interests focus on the pharmacology and management of asthma and COPD. He is editor-in-chief of Respiratory Medicine and associate editor of other journals such as Lung. Dr. Hanania has received multiple awards such as the ACCP’s Distinguished Scholar in Respiratory Health and the ACCP Humanitarian Award. Furthermore, he is principal investigator for the American Lung Association ACRC and COPD Gene study at Baylor.
Applying the Latest Guidelines and Recommendations to Initiate Biologic Therapy and Control Moderate-to-Severe Asthma SymptomsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA).
ACKNOWLEDGEMENTThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
LIVE RELEASE DATETuesday, November 29, 2022, from 2:00-3:00pm ET
TARGET AUDIENCEThe educational design of this activity addresses the needs of allergists, immunologists, pulmonologists, nurse practitioners and physician assistants involved in the treatment of patients with moderate-to-severe asthma.
STATEMENT OF NEED/PROGRAM OVERVIEWWhen managing patients with moderate-to-severe uncontrolled asthma, clinicians must select from 6 biologics with unique mechanisms of action targeting T2 inflammation. However, a lack of head-to-head trials means there is limited guidance to select the right agent for the right patient. To offer precision medicine, treatment plans must be individualized and an improved understanding of the impacts of asthma phenotypes/endotypes and T2 comorbidities must be incorporated into each treatment decision.
Join a panel of expert clinicians on the management of moderate-to-severe asthma to review the burden of uncontrolled asthma and the need to identify phenotypes and endotypes with an emphasis on T2 inflammation. Panelists will discuss current data on the efficacy and safety of biologics, including real-world evidence and relevance to biologic selection in the management of moderate-to-severe asthma. The session will conclude with 3 mini-case discussions, featuring different scenarios and patient presentations (biomarker levels, presence of comorbidities) and exploring related impacts on therapy selection.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Describe the role of T2 inflammation in asthma pathophysiology
- Identify patients with uncontrolled moderate-to-severe asthma who could benefit from addition of a biologic agent
- Summarize safety, efficacy, and long-term data for biologics used to manage patients with moderate-to-severe asthma and comorbid T2 inflammatory conditions
- Initiate a biologic agent for a patient with uncontrolled moderate-to-severe asthma based on current evidence from clinical trials, real-world experience, and up-to-date guidelines and recommendations
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 60 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor for Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Consulting Fee (e.g., Advisory Board): AstraZeneca, Genentech, TEVA
Contracted Research: AstraZeneca, TEVA, MedImmune, AgoMab, Janssen, Vault Health
Speakers' Bureau: AstraZeneca, Sanofi, Merck
Nicola A. Hanania, MD, MS
Professor of Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief, Pulmonary and Critical Care
Ben Taub Hospital
Consulting Fee (e.g., Advisory Board): Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Sanofi, and Teva
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Sanofi
Speakers' Bureau: Regeneron
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Carole Drexel Nothing to disclose Colleen Heffner Nothing to disclose Stephanie Puccio Nothing to disclose Kelsey O’Driscoll – Patient Participant Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
Technical Support:For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.